Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Alfuzosin

Criteria

Inclusion Criteria:

• male patients suffering from LUTS lasting 6months and over

• male patients aged 50 years old and over who has a continuous active partner

Exclusion Criteria:

• Primary hypogonadism and neuropathy patients

• History of prostate surgery

• Patients with prostate cancer

• History of organ surgery or organ damage in pelvis

• History of myocardiac infarction, stroke, and life threatening arrythmia within last 6 months

• Patients with haematuria caused by other reasons except BPH

• Patients with uncontrolled hypertension in spite of treatment with antihypertensive agents

• History of a malignant tumor within last 5 years

• Patients who are currently controlled with other medication for erectile dysfunction

• Patients who have been administered with androgen or antiandrogen

• Patients who is treated for psychiatric disorder or depression

• Combination with other alpha1-blockers

• Patients previously not improved by an alpha1-blocker treatment

• Known hypersensitivity to the alfuzosin

• History of postural hypotension or syncope

• Hepatic insufficiency

• Unstable angina pectoris

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.